trial

Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia

NCTId NCT01598896
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Terminated
Enrollment 12 (actual)
Sponsored by Mclean Hospital
Primary completion 2017-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Terminated
Enrollment
12 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2012-05
Primary completion
2017-08
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
DronabinolClonidine

Sponsors

Mclean HospitalLead Sponsor
Brain & Behavior Research FoundationCollaborator

Investigators

1
Kevin P Hill, MD, MHSPrincipal Investigator

Sites

1 total
Belmont, United States

Linked catalysts

1
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With — primary completion2017-08

Facts & assertions

4 sourced
Enrollment
12
Phase
PHASE2,PHASE3
Primary Completion Date
2017-08
Status
TERMINATED
relationships
The graph out of here
drug
Dronabinol
drug
Clonidine
drug
lead_sponsor
Mclean Hospital
company
collaborator
Brain & Behavior Research Foundation
company
indication
Cannabis Dependence
indication
Schizophrenia
indication
Marijuana Dependence
indication
investigator
Kevin P Hill, MD, MHS
person